Since it was founded in 1980, the International Conference of Drug Regulatory Authorities (ICDRA) has brought together regulatory authorities from WHO Member States to strengthen collaboration and develop international consensus on regulatory priorities. ICDRA provides a unique forum to support and guide regulatory authorities, WHO and international stakeholders in confronting the challenges and highlighting the opportunities of today’s dynamic and innovative regulatory sector.

Delegates from regulatory authorities around the world will participate in an event programme designed to evoke ideas and discussion on the current key priorities in the regulatory environment while also ensuring valuable engagement with leading stakeholders across industry, research as well as healthcare professionals in the open pre-ICDRA conference.

The 19th ICDRA will facilitate focused discussions on quality issues, regulatory reforms and strengthening regulatory systems, safety of medical products, detection, prevention and response to substandard and falsified medical products, access to quality medical products, smart regulation of clinical trials, regulatory collaboration, harmonization, rationalization and reliance, access to new and novel technologies, regulation of novel medical products, regulation of herbal medicines, etc.

The theme of the conference: Smart Regulation: Delivering Quality Assured Medical Products for All”.

The Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Govt. of India, in collaboration with World Health Organization (WHO) is hosting “19th International Conference of Drug Regulatory Authorities (ICDRA)” in New Delhi, India, 14th October- 18th October 2024”. The theme of this ICDRA is “Smart Regulation: Delivering Quality Assured Medical Products for All”. The event is a full five (5) day program, wherein the first 2 days are designated as PRE-ICDRA and the remaining 3 days are designated as ICDRA.

Pre-ICDRA is an open session, wherein the delegates and participants from Drugs Regulatory Authorities, Governments and inter-government organizations, Industries, Academia, Research organizations, NGOs, Non-profit organizations etc., while ICDRA is a REGULATORS ONLY session open for Drug Regulatory Authorities of WHO Member States.

The interested participants may register themselves on this portal and may follow subsequent communications related to confirmation of registration. On the side-lines of Pre-ICDRA, A few industry and research organizations may register themselves as EXHIBITORS to showcase their products/processes to the Drug Regulatory Authority community. The participants/exhibitors may refer to the Registration Manual prior to initiating the registration process.

The international participants, after successful registration, may be issued with specific VISA support letters from ICDRA Secretariat to facilitate the VISA issuance by Indian Embassies in the country.

Central Drugs Standard Control Organization, on behalf of Ministry of Health and Family Welfare, Govt. of India and World Health Organization (WHO) is delighted to invite you to participate in the 19th International Conference of Drug Regulatory Authorities (ICDRA) in New Delhi, India. You are requested to register at the earliest, as the seats are limited.

For any further clarifications, you may contact ICDRA Secretariat at support[at]icdra2024[dot]in

Dear Delegates,

You are cordially invited to participate in the "19th International Conference of Drug Regulatory Authorities (ICDRA)” in New Delhi, India, 14th October- 18th October 2024” being organized by Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Govt. of India, in collaboration with World Health Organization (WHO).

Friends, India was to host this event in 2020, however, due to COVID-19 pandemic, this important drugs regulatory event could not be convened. Now that situations have been normalized, we are eager to welcome and host the conference for deliberating important agenda points.

Drug Regulatory Authorities are vested with the prime responsibility of making the timely availability of high quality, safe and efficacious drugs for their population. Such conferences will offer a platform to discuss the relevant issues and also to build each other’s trust for regulatory reliance and harmonization of regulatory practices.

Once again, I invite and urge your participation to this international conference.

Dear Colleagues,

It gives me immense gratitude to announce that Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Govt. of India is hosting the 19th International Conference of Drugs Regulatory Authorities (ICDRA) in New Delhi India from 14th October to 18th October 2024 in collaboration with World Health Organization (WHO). You are aware that we had to postpone this event in the year 2020 due to COVD-19 pandemic, however, WHO had organized the Extraordinary Virtual International Conference of Drug Regulatory Authorities (ICDRA), from 20th - 24th September, 2021 and we were glad to share our experiences and best practices.

I take a great pride in welcoming the eminent Drugs Regulators from all over the world, renowned scientists, academicians, researchers, NGOs, consumer representatives, delegates of leading national & international pharmaceutical companies, non-profit organizations etc. to participate to the largest and prestigious gatherings for drug regulatory authorities.

Theme of the 19th ICDRA is “Smart Regulation: Delivering Quality Assured Medical Products for All”, which is very relevant to our collective responsibility towards making the timely availability of high quality, efficacious and safe medicines for entire healthcare ecosystem. Apart from this, the pandemic has also taught us to adopt the expedited and accelerated pathways for approval of drugs, diagnostics, and vaccines, which was based on the rigorous coordination and collaboration, harmonized processes, and regulatory reliance. Everyone appreciates that smart and risk based regulations are the need of the hour in light of resource constraints including workforce, making us to judiciously utilize them for newer requirements and to rely upon other regulators for established things.

I am sure that, the deliberations of 19th ICDRA will be more fruitful to provide concrete recommendations to NRAs, Governments of member countries and WHO for ensuring quick access to high quality medical products for all.